CG5/Dx human breast cancer cell line: Characterization of a new doxorubicin-resistant variant

Nadia Gibelli, Carlo Zibera, Annalia Asti, Luciano Maestri, Luisa Bacchella, Paolo Pedrazzoli, Alberto Calligaro, Gioacchino Robustelli Della Cuna

Research output: Contribution to journalArticle

Abstract

By continuous exposure of CG5 human breast cancer cell line to increasing doxorubicin (Dx) concentrations, a multidrug-resistant (MDR) subline (CGS/Dx) was obtained. The resistant variant showed P-glycoprotein (P-gp) expression and a lower intracellular doxorubicin level than the parental cells. CGS/Dx cells were 19.4 fold more resistant to Dx than CG5 cells and showed a cross-resistance to some structurally related and unrelated compounds. Differences in kinetics, biological and ultrastructural features between the two cell lines were investigated. The CGS/Dx cells grew more slowly, produced higher CEA levels and showed a reduced progesterone receptor (PgR) content than the parental cells. Ultrastructural studies revealed differences involving, polyribosomes, rough endoplasmic reticulum, [mithocondria] and cytoskeleton.

Original languageEnglish
Pages (from-to)1675-1681
Number of pages7
JournalAnticancer Research
Volume16
Issue number4 A
Publication statusPublished - Jul 1996

Keywords

  • Breast cancer
  • Doxorubicin
  • Multidrug-resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'CG5/Dx human breast cancer cell line: Characterization of a new doxorubicin-resistant variant'. Together they form a unique fingerprint.

  • Cite this

    Gibelli, N., Zibera, C., Asti, A., Maestri, L., Bacchella, L., Pedrazzoli, P., Calligaro, A., & Robustelli Della Cuna, G. (1996). CG5/Dx human breast cancer cell line: Characterization of a new doxorubicin-resistant variant. Anticancer Research, 16(4 A), 1675-1681.